iSign Solutions (ISGN) 10-Q 15 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 15, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	iSign Solutions Inc.
Entity Central Index Key	0000727634
Trading Symbol	ISGN
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019
Entity Filer Category	Non-accelerated Filer
Entity Ex Transition Period	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		5,761,980

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 280	$ 335
Accounts receivable, net of allowance of $1 at March 31, 2019 and $1 at December 31, 2018, respectively	43	84
Prepaid expenses and other current assets	59	46
Total current assets	382	465
Property and equipment, net	3	2
Other assets	5	5
Total assets	390	472
Current liabilities:
Accounts payable	1,266	1,280
Short-term debt, net	2,220	2,210
Accrued compensation	78	81
Other accrued liabilities	598	524
Deferred revenue	362	281
Total current liabilities	4,524	4,376
Deferred revenue long-term		36
Other long-term liabilities	703	665
Total liabilities	5,227	5,077
Commitments and contingencies
Stockholders' equity (deficit):
Common stock, $0.01 par value; 2,000,000 shares authorized; 5,760 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively	58	58
Treasury shares, 5 at March 31, 2019 and December 31, 2018, respectively	(325)	(325)
Additional paid in capital	129,310	129,251
Accumulated deficit	(133,880)	(133,589)
Total stockholders' deficit	(4,837)	(4,605)
Total liabilities and stockholders' deficit	$ 390	$ 472

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance	$ 1	$ 1
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	2,000,000	2,000,000
Common stock, shares issued	5,760	5,760
Common stock, shares outstanding	5,760	5,760
Treasury shares	5	5

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue:
Product	$ 41	$ 40
Maintenance	158	174
Total revenue	199	214
Cost of sales:
Product	2	3
Maintenance	16	7
Research and development	171	229
Sales and marketing	26	19
General and administrative	204	176
Total operating costs and expenses	419	434
Loss from operations	(220)	(220)
Interest expense:
Related party	(14)	(8)
Other	(47)	(30)
Amortization of debt discount:
Related party	(3)	(7)
Other	(7)	(17)
Loss before income tax expense	(291)	(282)
Income tax expense		(2)
Net loss	$ (291)	$ (284)
Basic and diluted net loss per common share	$ (0.05)	$ (0.05)
Weighted average common shares outstanding, basic and diluted	5,762	5,762

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2017	$ 58	$ (325)	$ 129,027	$ (132,562)	$ (3,802)
Balance, shares at Dec. 31, 2017	5,760	5
Stock-based compensation			48		48
Net loss				(284)	(284)
Balance at Mar. 31, 2018	$ 58	$ (325)	129,075	(132,846)	(4,038)
Balance, shares at Mar. 31, 2018	5,760	5
Balance at Dec. 31, 2018	$ 58	$ (325)	129,251	(133,589)	(4,605)
Balance, shares at Dec. 31, 2018	5,760	5
Stock-based compensation			59		59
Net loss				(291)	(291)
Balance at Mar. 31, 2019	$ 58	$ (325)	$ 129,310	$ (133,880)	$ (4,837)
Balance, shares at Mar. 31, 2019	5,760	5

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (291)	$ (284)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1	2
Stock-based compensation	59	48
Amortization of debt discount	10	24
Changes in operating assets and liabilities:
Accounts receivable, net	41	14
Prepaid expenses and other assets	(13)	6
Accounts payable	(14)	(14)
Accrued compensation	(3)	(54)
Other accrued and long-term liabilities	112	79
Deferred revenue	45	10
Net cash used in operating activities	(53)	(169)
Cash flows from investing activities:
Acquisition of property and equipment	(2)
Net cash used in investing activities	(2)
Net decrease in cash and cash equivalents	(55)	(169)
Cash and cash equivalents at beginning of period	335	285
Cash and cash equivalents at end of period	280	116
Supplementary disclosure of cash flow information
Interest paid	1
Income taxes paid		$ 2

Nature of Business and Summary

Nature of Business and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Nature of Business and Summary of Significant Accounting Policies	1. Nature of Business and Summary of Significant Accounting Policies Nature of Business iSign Solutions Inc. and its subsidiary is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management and authentication of document-based transactions. iSign's solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. iSign's platform can be deployed both on premise and as a cloud-based ("SaaS") service, with the ability to easily transition between deployment models. The Company is headquartered in San Jose, California. The Company's products include SignatureOne™ Ceremony™ Server, the iSign™ suite of products and services, including iSign™ Enterprise and iSign™ Console™, and Sign-it™ programs. Basis of Presentation The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2018. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company's results of operations and cash flows for the periods presented. The Company's interim results are not necessarily indicative of the results to be expected for the entire year. Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at March 31, 2019 the Company's accumulated deficit was $133,880. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of March 31, 2019, the Company's cash balance was $280. These factors raise substantial doubt about the Company's ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accounting Changes and Recent Accounting Pronouncements Accounting Standards Update No. 2019-01, Leases (Topic 842), Codification Improvements. The amendments in this Update include the following items: (1) determining the fair value of the underlying asset by lessors that are not manufacturers or dealers; (2) presentation on the statement of cash flows—sales-type and direct financing leases; and (3) transition disclosures related to Topic 250, Accounting Changes and Error Corrections. The amendments in ASU 2019-01 for Issue 1 affect all lessors that are not manufacturers or dealers (generally financial institutions and captive finance companies); for Issue 2, all lessors that are depository and lending entities within the scope of Topic 942; for Issue 3, all entities that are lessees or lessors. The effective date of the amendments in ASU 2019-01 are for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2019-01 effective January 1, 2019. The adoption of ASU 2019-01 will have no impact on the Company's financial statements.

Concentrations

Concentrations	3 Months Ended
	Mar. 31, 2019
Risks and Uncertainties [Abstract]
Concentrations	2. Concentrations The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable Total Revenue 2019 2018 2019 2018 Customer #1 – – 12 % 14 % Customer #2 83 % 76 % 17 % 11 % Customer #3 – – 18 % 16 % Customer #4 – – 20 % 20 % Customer #5 – 16 % – – Total concentration 83 % 92 % 67 % 61 %

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Net Loss Per Share	3. Net Loss Per Share The Company calculates basic net loss per share based on the weighted average number of shares outstanding, and when applicable, diluted net income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding. The following table lists shares and warrants that were excluded from the calculation of diluted earnings per share as the inclusion of shares from the assumed exercise of such options and warrants would be anti-dilutive: For the Three Months Ended March 31, March 31, Stock options 1,077 736 Warrants 2,813 1,839

Debt

Debt	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Debt	4. Debt Advances: In April, May, and June 2018, the Company received, from investors, advances aggregating $115 in cash against certain accounts receivable of the Company. Upon collection of an invoice, the Company would repay the advance to the lenders on a pro rata basis together with a 5% advance fee. The receivables were collected and $40 of the advances were repaid in May 2018, along with $2 in advance fees per the agreement. The advance fees were recorded as interest expense in the quarter ended June 30, 2018. The remaining $75 advances were converted into secured convertible notes in August 2018. Notes payable: In August 2018, the Company issued secured convertible promissory notes to investors and affiliates of the Company aggregating $341, of which $205 was paid in cash, $75 was exchanged for the remaining advances described above and $61 was in the form of an Original Issue Discount ("OID") on these amounts. The secured notes are mandatorily convertible into Common Stock at a conversion rate of the lesser of $0.50 per share or the price per share of Common Stock upon closing a new financing of at least $1,000 in aggregate proceeds. The secured notes bear interest at the rate of 10% per annum, are due December 31, 2019 and are secured by an interest in all the Company's rights, title and interest in, to and under its intellectual property. Should the secured notes remain outstanding following the maturity date an additional 30% of the note's principal amount shall become due and payable. In December 2018, the Company issued short-term unsecured convertible promissory notes to investors and affiliates of the Company aggregating $346 in cash. The short-term notes are mandatorily convertible into Common Stock at a conversion rate of the lesser of $0.50 per share or the price per share of Common Stock, upon closing a new debt and/or equity financing of at least $1,000 in aggregate proceeds. The notes bear interest at the rate of 10% per annum and are due December 31, 2019. The Company used the funds received from the above financing for working capital and general corporate purposes. During the three months ended March 31, 2019, the Company accrued $61 of interest expense, $53 associated with the notes, of which $13 was to related parties and $40 was to other investors. For the three months ended March 31, 2018, the Company accrued $38 of interest expense, $32 associated with the notes, of which $8 was to related parties and $24 was to other investors. The Company recorded $10 and $24 in debt discount amortization for the three months ended March 31, 2019 and 2018, respectively.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Stockholders' Equity (Deficit)	5. Stockholders' Equity (Deficit) Stock-based compensation expense is based on the estimated grant date fair value of the portion of stock-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black-Scholes-Merton valuation model. Forfeitures of stock-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the three months ended March 31, 2019 and 2018 was approximately 0.11% and 5.95%, respectively, based on historical data. Valuation and Expense Information: The weighted-average fair value of stock-based compensation is based on the Black-Scholes-Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized over the vesting period of the options. The Company granted stock options to purchase 40,000 shares of common stock during the three months ended March 31, 2019. No options were granted during the three months ended March 31, 2018. There were no stock options exercised during the three months ended March 31, 2019 and 2018, respectively. The fair value calculations for the stock options granted are based on the following assumptions: Three Months Ended Risk free interest rate 2.30 % Expected life (years) 6.1 Expected volatility 191.65 % Expected dividend yield None The following table summarizes the allocation of stock-based compensation expense for the three months ended March 31: 2019 2018 Research and development $ 10 $ 31 Sales and marketing – – General and administrative 40 13 Director 9 4 Total stock-based compensation $ 59 $ 48 A summary of option activity under the Company's plans for the three months ended March 31, 2019 and 2018 is as follows: 2019 2018 Options Shares Weighted Average Exercise Price per share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Shares Weighted Average Exercise Price per share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1 1,037 $ 1.65 – $ – 736 $ 3.65 – – Granted 40 $ 0.50 – – – $ – – – Outstanding at March 31 1,077 $ 1.61 5.72 $ – 736 $ 3.65 6.11 – Vested and expected to vest at March 31 1,077 $ 1.61 5.72 $ – 702 $ 3.86 6.09 $ – Exercisable at March 31 402 $ 3.24 5.28 $ – 153 $ 15.67 4.82 $ – The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2019: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Number Outstanding Weighted Average Exercise Price $0.01 - $0.50 655 5.49 $ 0.50 307 $ 0.50 $0.51 - $1.00 393 6.36 0.78 66 0.78 $1.01 - $25.00 2 3.33 15.94 2 15.94 $25.00 - $625.00 27 2.00 38.81 27 38.81 Total 1,077 5.72 1.61 402 3.24 A summary of the status of the Company's non-vested shares as of March 31, 2019 is as follows: Non-vested Shares Shares Weighted Average Grant-Date Fair Value Non-vested at January 1, 2019 718 $ 0.54 Granted 40 $ 0.50 Vested (83 ) $ 0.65 Non-vested at March 31, 2019 675 $ 0.52 As of March 31, 2019, there was $127 of total unrecognized compensation expense related to non-vested stock-based compensation arrangements granted under the plans. The unrecognized compensation expense is expected to be realized over a weighted average period of 2.60 years. Warrants On February 6, 2019, the Company issued warrants to purchase 985,000 shares of common stock to 4 consultants and an employee in connection with the accrued compensation owed by the Company to the employee and consultants. The warrants are exercisable for three years with an exercise price of $0.50 per share. The warrants may not be exercised for cash or on a cashless basis, and may solely be exercised using the holder's outstanding accrued compensation on the date of exercise. A summary of the warrant activity to purchase shares of Common Stock for the three months ended March 31 is as follows: 2019 2018 Shares Weighted Average Exercise Price Shares Weighted Average Exercise Price Outstanding at beginning of period 1,828 $ 2.08 1,878 $ 2.46 Issued 985 $ 0.50 – $ – Expired/Canceled – $ – (39 ) $ 15.63 Outstanding at end of period 2,813 $ 1.53 1,839 $ 2.18 Exercisable at end of period 2,813 $ 1.53 1,839 $ 2.18 A summary of the status of the warrants outstanding and exercisable to purchase shares of Common Stock as of March 31, 2019 is as follows: Number of Shares Weighted Average Weighted Average 1,551 2.2 $ 2.18 277 0.5 $ 1.63 985 2.9 $ 0.50 2,813 2.3 $ 1.53

Nature of Business and Summar_2

Nature of Business and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Nature of Business	Nature of Business iSign Solutions Inc. and its subsidiary is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management and authentication of document-based transactions. iSign's solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. iSign's platform can be deployed both on premise and as a cloud-based ("SaaS") service, with the ability to easily transition between deployment models. The Company is headquartered in San Jose, California. The Company's products include SignatureOne™ Ceremony™ Server, the iSign™ suite of products and services, including iSign™ Enterprise and iSign™ Console™, and Sign-it™ programs.
Basis of Presentation	Basis of Presentation The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2018. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company's results of operations and cash flows for the periods presented. The Company's interim results are not necessarily indicative of the results to be expected for the entire year.
Going Concern	Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at March 31, 2019 the Company's accumulated deficit was $133,880. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of March 31, 2019, the Company's cash balance was $280. These factors raise substantial doubt about the Company's ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Accounting Changes and Recent Accounting Pronouncements	Accounting Changes and Recent Accounting Pronouncements Accounting Standards Update No. 2019-01, Leases (Topic 842), Codification Improvements. The amendments in this Update include the following items: (1) determining the fair value of the underlying asset by lessors that are not manufacturers or dealers; (2) presentation on the statement of cash flows—sales-type and direct financing leases; and (3) transition disclosures related to Topic 250, Accounting Changes and Error Corrections. The amendments in ASU 2019-01 for Issue 1 affect all lessors that are not manufacturers or dealers (generally financial institutions and captive finance companies); for Issue 2, all lessors that are depository and lending entities within the scope of Topic 942; for Issue 3, all entities that are lessees or lessors. The effective date of the amendments in ASU 2019-01 are for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2019-01 effective January 1, 2019. The adoption of ASU 2019-01 will have no impact on the Company's financial statements.

Concentrations (Tables)

Concentrations (Tables)	3 Months Ended
	Mar. 31, 2019
Risks and Uncertainties [Abstract]
Summary of accounts receivable and revenue concentrations	Accounts Receivable Total Revenue 2019 2018 2019 2018 Customer #1 – – 12 % 14 % Customer #2 83 % 76 % 17 % 11 % Customer #3 – – 18 % 16 % Customer #4 – – 20 % 20 % Customer #5 – 16 % – – Total concentration 83 % 92 % 67 % 61 %

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Schedule of antidilutive excluded from calculation of earnings per share	For the Three Months Ended March 31, March 31, Stock options 1,077 736 Warrants 2,813 1,839

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Schedule of fair value calculations for the stock options granted	Three Months Ended Risk free interest rate 2.30 % Expected life (years) 6.1 Expected volatility 191.65 % Expected dividend yield None
Schedule of allocation of stock-based compensation expense	2019 2018 Research and development $ 10 $ 31 Sales and marketing – – General and administrative 40 13 Director 9 4 Total stock-based compensation $ 59 $ 48
Schedule of option activity under the Company's plans	2019 2018 Options Shares Weighted Average Exercise Price per share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Shares Weighted Average Exercise Price per share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1 1,037 $ 1.65 – $ – 736 $ 3.65 – – Granted 40 $ 0.50 – – – $ – – – Outstanding at March 31 1,077 $ 1.61 5.72 $ – 736 $ 3.65 6.11 – Vested and expected to vest at March 31 1,077 $ 1.61 5.72 $ – 702 $ 3.86 6.09 $ – Exercisable at March 31 402 $ 3.24 5.28 $ – 153 $ 15.67 4.82 $ –
Schedule of significant ranges of outstanding and exercisable options	Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Number Outstanding Weighted Average Exercise Price $0.01 - $0.50 655 5.49 $ 0.50 307 $ 0.50 $0.51 - $1.00 393 6.36 0.78 66 0.78 $1.01 - $25.00 2 3.33 15.94 2 15.94 $25.00 - $625.00 27 2.00 38.81 27 38.81 Total 1,077 5.72 1.61 402 3.24
Schedule of the company's non-vested shares	Non-vested Shares Shares Weighted Average Grant-Date Fair Value Non-vested at January 1, 2019 718 $ 0.54 Granted 40 $ 0.50 Vested (83 ) $ 0.65 Non-vested at March 31, 2019 675 $ 0.52
Schedule of warrant activity to purchase shares of common stock	2019 2018 Shares Weighted Average Exercise Price Shares Weighted Average Exercise Price Outstanding at beginning of period 1,828 $ 2.08 1,878 $ 2.46 Issued 985 $ 0.50 – $ – Expired/Canceled – $ – (39 ) $ 15.63 Outstanding at end of period 2,813 $ 1.53 1,839 $ 2.18 Exercisable at end of period 2,813 $ 1.53 1,839 $ 2.18
Schedule of warrants outstanding and exercisable to purchase shares of common stock	Number of Shares Weighted Average Weighted Average 1,551 2.2 $ 2.18 277 0.5 $ 1.63 985 2.9 $ 0.50 2,813 2.3 $ 1.53

Nature of Business and Summar_3

Nature of Business and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies (Textual)
Accumulated deficit	$ (133,880)	$ (133,589)
Cash balance	$ 280	$ 335	$ 116	$ 285

Concentrations (Details)

Concentrations (Details)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Accounts Receivable [Member]
Concentration Risk [Line Items]
Total concentration	83.00%	92.00%
Accounts Receivable [Member] | Customer #1 [Member]
Concentration Risk [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #2 [Member]
Concentration Risk [Line Items]
Total concentration	83.00%	76.00%
Accounts Receivable [Member] | Customer #3 [Member]
Concentration Risk [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #4 [Member]
Concentration Risk [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #5 [Member]
Concentration Risk [Line Items]
Total concentration		16.00%
Total Revenue [Member]
Concentration Risk [Line Items]
Total concentration	67.00%	61.00%
Total Revenue [Member] | Customer #1 [Member]
Concentration Risk [Line Items]
Total concentration	12.00%	14.00%
Total Revenue [Member] | Customer #2 [Member]
Concentration Risk [Line Items]
Total concentration	17.00%	11.00%
Total Revenue [Member] | Customer #3 [Member]
Concentration Risk [Line Items]
Total concentration	18.00%	16.00%
Total Revenue [Member] | Customer #4 [Member]
Concentration Risk [Line Items]
Total concentration	20.00%	20.00%
Total Revenue [Member] | Customer #5 [Member]
Concentration Risk [Line Items]
Total concentration

Net Loss Per Share (Details)

Net Loss Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Stock options [Member]
Net Loss Per Share (Textual)
Anti-diluted earnings per share of stock options and warrants shares	1,077	736
Warrants [Member]
Net Loss Per Share (Textual)
Anti-diluted earnings per share of stock options and warrants shares	2,813	1,839

Debt (Details)

Debt (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended					3 Months Ended
	Dec. 31, 2018	Aug. 31, 2018	Jun. 30, 2018	May 31, 2018	Apr. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Aggregating amount of debt			$ 115	$ 115	$ 115
Debt instrument, description						Upon collection of an invoice, the Company would repay the advance to the lenders on a pro rata basis together with a 5% advance fee. The receivables were collected and $40 of the advances were repaid in May 2018, along with $2 in advance fees per the agreement. The advance fees were recorded as interest expense in the quarter ended June 30, 2018. The remaining $75 advances were converted into secured convertible notes in August 2018.
Accrued interest expense						$ 61	$ 38
Accrues interest associated with the notes						53	32
Accrued interest to related parties						13	8
Accrued Interest to other investors						40	24
Amortization of debt discount						$ 10	$ 24
Secured Convertible Promissory Notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Aggregating amount of debt	$ 346	$ 205
Debt instrument, description		The maturity date an additional 30% of the note's principal amount shall become due and payable.
Issued secured convertible promissory notes		$ 341
Conversion rate per shares	$ 0.50	$ 0.50
Aggregate proceeds of new financing	$ 1,000	$ 1,000
Secured notes bear interest rate	10.00%	10.00%
Secured notes due date	Dec. 31, 2019	Dec. 31, 2019
Original issue discounts		$ 61
Amount exchanged for advances		$ 75

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) (Details)	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Risk free interest rate	2.30%
Expected life (years)	6 years 1 month 6 days
Expected volatility	191.65%
Expected dividend yield

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense included in operating expenses	$ 59	$ 48
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense included in operating expenses	10	31
Sales and marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense included in operating expenses
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense included in operating expenses	40	13
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense included in operating expenses	$ 9	$ 4

Stockholders' Equity (Deficit_4

Stockholders' Equity (Deficit) (Details 2) - Option [Member] - USD ($) shares in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Shares
Outstanding, Beginning balance	1,037	736
Granted	40
Outstanding, Ending Balance	1,077	736
Vested and expected to vest, Ending balance	1,077	702
Exercisable, Ending balance	402	153
Weighted Average Exercise Price Per share
Outstanding, Beginning balance	$ 1.65	$ 3.65
Granted	0.50
Outstanding, Ending balance	1.61	3.65
Vested and expected to vest, Ending balance	1.61	3.86
Exercisable, Ending balance	$ 3.24	$ 15.67
Weighted Average Remaining Contractual Term (Years)
Outstanding, Ending balance	5 years 8 months 19 days	6 years 1 month 9 days
Vested and expected to vest, Ending balance	5 years 8 months 19 days	6 years 1 month 2 days
Exercisable, Ending balance	5 years 3 months 11 days	4 years 9 months 25 days
Aggregate Intrinsic Value
Outstanding, Beginning balance
Granted
Outstanding, Ending balance
Vested and expected to vest, Ending balance
Exercisable, Ending balance

Stockholders' Equity (Deficit_5

Stockholders' Equity (Deficit) (Details 3) shares in Thousands	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	1,077
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	5 years 8 months 19 days
Options Outstanding, Weighted Average Exercise Price	$ 1.61
Options Exercisable, Number Outstanding | shares	402
Options Exercisable, Weighted Average Exercise Price	$ 3.24
$0.01 - $0.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	0.01
Range of Exercise Prices, Upper Range Limit	$ 0.50
Options Outstanding, Number Outstanding | shares	655
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	5 years 5 months 27 days
Options Outstanding, Weighted Average Exercise Price	$ 0.50
Options Exercisable, Number Outstanding | shares	307
Options Exercisable, Weighted Average Exercise Price	$ 0.50
$0.51 - $1.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	0.51
Range of Exercise Prices, Upper Range Limit	$ 1
Options Outstanding, Number Outstanding | shares	393
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	6 years 4 months 9 days
Options Outstanding, Weighted Average Exercise Price	$ 0.78
Options Exercisable, Number Outstanding | shares	66
Options Exercisable, Weighted Average Exercise Price	$ 0.78
$1.01 - $25.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	1.01
Range of Exercise Prices, Upper Range Limit	$ 25
Options Outstanding, Number Outstanding | shares	2
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	3 years 3 months 29 days
Options Outstanding, Weighted Average Exercise Price	$ 15.94
Options Exercisable, Number Outstanding | shares	2
Options Exercisable, Weighted Average Exercise Price	$ 15.94
$25.00 - $625.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	25
Range of Exercise Prices, Upper Range Limit	$ 625
Options Outstanding, Number Outstanding | shares	27
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	2 years
Options Outstanding, Weighted Average Exercise Price	$ 38.81
Options Exercisable, Number Outstanding | shares	27
Options Exercisable, Weighted Average Exercise Price	$ 38.81

Stockholders' Equity (Deficit_6

Stockholders' Equity (Deficit) (Details 4) shares in Thousands	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Shares
Non-vested, Beginning balance | shares	718
Granted | shares	40
Vested | shares	(83)
Non-vested, Ending balance | shares	675
Weighted Average Grant-Date Fair Value
Non-vested, Beginning balance | $ / shares	$ 0.54
Granted | $ / shares	0.50
Vested | $ / shares	0.65
Non-vested, Ending balance | $ / shares	$ 0.52

Stockholders' Equity (Deficit_7

Stockholders' Equity (Deficit) (Details 5) - Warrant [Member] - $ / shares shares in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Outstanding at beginning of period	1,828	1,878
Shares, Issued	985
Shares, Expired/Canceled		(39)
Shares, Outstanding at end of period	2,813	1,839
Shares, Exercisable at end of period	2,813	1,839
Weighted Average Exercise Price Per Share, Outstanding at beginning of period	$ 2.08	$ 2.46
Weighted Average Exercise Price Per Share, Issued	0.50
Weighted Average Exercise Price Per Share, Expired/Canceled		15.63
Weighted Average Exercise Price Per Share, Outstanding at end of period	1.53	2.18
Weighted Average Exercise Price Per Share, Exercisable at end of period	$ 1.53	$ 2.18

Stockholders' Equity (Deficit_8

Stockholders' Equity (Deficit) (Details 6) shares in Thousands	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Class of Warrant or Right [Line Items]
Number of Shares Outstanding and Exercisable | shares	2,813
Weighted Average Remaining Life (in years)	2 years 3 months 19 days
Weighted Average Exercise Price per share | $ / shares	$ 1.53
Warrants Group One [Member]
Class of Warrant or Right [Line Items]
Number of Shares Outstanding and Exercisable | shares	1,551
Weighted Average Remaining Life (in years)	2 years 2 months 12 days
Weighted Average Exercise Price per share | $ / shares	$ 2.18
Warrants Group Two [Member]
Class of Warrant or Right [Line Items]
Number of Shares Outstanding and Exercisable | shares	277
Weighted Average Remaining Life (in years)	6 months
Weighted Average Exercise Price per share | $ / shares	$ 1.63
Warrants Group Three [Member]
Class of Warrant or Right [Line Items]
Number of Shares Outstanding and Exercisable | shares	985
Weighted Average Remaining Life (in years)	2 years 10 months 25 days
Weighted Average Exercise Price per share | $ / shares	$ 0.50

Stockholders' Equity (Deficit_9

Stockholders' Equity (Deficit) (Details Textual) - USD ($) shares in Thousands, $ in Thousands	Feb. 06, 2019	Mar. 31, 2019	Mar. 31, 2018
Stockholders' Equity (Deficit) (Textual)
Common stock granted, Shares		40,000
Total unrecognized compensation cost		$ 127
Weighted average period		2 years 7 months 6 days
Estimated average forfeiture rate		0.11%	5.95%
Warrant, Description	The Company issued warrants to purchase 985,000 shares of common stock to 4 consultants and an employee in connection with the accrued compensation owed by the Company to the employee and consultants. The warrants are exercisable for three years with an exercise price of $0.50 per share. The warrants may not be exercised for cash or on a cashless basis, and may solely be exercised using the holder's outstanding accrued compensation on the date of exercise.